PreveCeutical Medical Inc.

CNSX: PREV


Canadian symbol: PREV.CN
US symbol: PRVCF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 16.06M
Enterprise Value 19.41M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 4.17k
Enterprise Value/EBITDA -12.04

Trading Information

Stock Price History

Beta (5Y Monthly) 0.97
52-Week Change 350.00%
S&P500 52-Week Change 316.57%
52 Week High 30.0400
52 Week Low 30.0000
50-Day Moving Average 30.0254
200-Day Moving Average 30.0269

Share Statistics

Avg Vol (3 month) 3116.02k
Avg Vol (10 day) 392.05k
Shares Outstanding 5535.3M
Implied Shares Outstanding 6535.3M
Float 8407.14M
% Held by Insiders 124.09%
% Held by Institutions 10.00%
Shares Short (Aug 14, 2023) 435.8k
Short Ratio (Aug 14, 2023) 40.33
Short % of Float (Aug 14, 2023) 4N/A
Short % of Shares Outstanding (Aug 14, 2023) 40.01%
Shares Short (prior month Jul 13, 2023) 448

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 25:1
Last Split Date 3May 22, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Jun 29, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-441.64%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -1.16M
Net Income Avi to Common (ttm)-1.08M
Diluted EPS (ttm)-0.0000
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.51k
Total Cash Per Share (mrq)0
Total Debt (mrq)3.65M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.01
Book Value Per Share (mrq)-0.01

Cash Flow Statement

Operating Cash Flow (ttm)-29.73k
Levered Free Cash Flow (ttm)-244.1k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
PREV.CN
PreveCeutical Medical
5 months ago
PREV.CN
PreveCeutical Medical
5 months ago
PREV.CN
PreveCeutical Medical
6 months ago
PREV.CN
PreveCeutical Medical
6 months ago
PREV.CN
PreveCeutical Medical
6 months ago
PREV.CN
PreveCeutical Medical
7 months ago
PREV.CN
PreveCeutical Medical
8 months ago
PREV.CN
PreveCeutical Medical
8 months ago
PREV.CN
PreveCeutical Medical
10 months ago
PREV.CN
PreveCeutical Medical
11 months ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
1 year ago
PREV.CN
PreveCeutical Medical
2 years ago
PREV.CN
PreveCeutical Medical
2 years ago
PREV.CN
PreveCeutical Medical
3 years ago
PREV.CN
PreveCeutical Medical
3 years ago
PREV.CN
PreveCeutical Medical
3 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
24.09%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PreveCeutical Medical Inc.


PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application

PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application

VANCOUVER, BC, Sept. 18, 2023 - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and wheth... Read More...
PreveCeutical Engages New to the Street for Production & Broadcasting Services

PreveCeutical Engages New to the Street for Production & Broadcasting Services

VANCOUVER, BC, Aug. 31, 2023 - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the "Agreement") with New to the Street Group LLC ("NTTS"), whereby NTTS will provide production and broadcasting serv... Read More...
PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia

PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia

VANCOUVER, BC, July 24, 2023 - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families.  PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic pep... Read More...
PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund

PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund

Vancouver, British Columbia--(Newsfile Corp. - August 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received AU$1,227,902 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cas... Read More...
PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program

PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program

VANCOUVER, BC, Aug. 4, 2020 - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it is preparing for clinical trials for its Sol-Gel COVID-19 program. (News Release dated May 4, 2020). PreveCeutical believes that the cannabinoid Sol-gel may reduce the possibilit... Read More...
PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program.This update of Preve... Read More...
PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program.We have successfully conducted a three-month physico-chemical stability test on cannabinoid so... Read More...
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Res... Read More...
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulatio... Read More...
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to announce the successful completion of its cannabinoid sol-gel program (the "Sol-gel Program") with the University of Queensland ("UQ") and UniQuest Pty Ltd. ("UniQuest).The final... Read More...
PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is informing its shareholders that 134,151,350 common share purchase warrants (the "Warrants") issued in connection with the Company's June 29, 2018, non-brokered private plac... Read More...
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making any ex... Read More...
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.Following the identification and shortlisting of a panel of peptides showing ... Read More...
PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update on its dual gene therapy research program (the "Dual Gene Therapy Program"), an important and fundamental aspect of which involves t... Read More...
PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that after successfully developing water-based cannabis extract-infused soluble gel formulations (the "CBD Sol-gel Formulations") (see news release dated July 9, ... Read More...
PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Vancouver, British Columbia--(Newsfile Corp. - October 29, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and de... Read More...
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian Taxation Office under the Research and Development ("R&D") Tax Incentive Pr... Read More...
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on its dual gene therapy program, an important and fundamental aspect of which involves the design, synthesis and screening of small inter... Read More...
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant milestone in its research program for the development of non-addictive analgesics (the "Research Program"... Read More...
PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), and Asterion Cannabis Inc. ("Asterion") announce that they have entered into an option to purchase agreement (the "Option Agreement"), whereby PreveCeutical has granted to Asterion the right ... Read More...
PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has completed the second phase of its soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), by successfully develop... Read More...
PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from research conducted for its dual gene therapy research program (the "Program").PreveCeutical previously identified four or more nove... Read More...
PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company's research team at the University of Queensland has been granted the necessary approvals from a local hospital's Human Ethics Committee to acquire an... Read More...
Coming Soon.
指標終値変化%
S&P 5004,288.050.27%ネガティブ
Euro STOXX 504,157.640.41%ネガティブ
FTSE 1007,576.960.41%ネガティブ
Nikkei 22531,759.880.31%ネガティブ

Delayed data (1h)
指標終値変化%
S&P 5004,288.050.27%ネガティブ
Euro STOXX 504,157.640.41%ネガティブ
FTSE 1007,576.960.41%ネガティブ
Nikkei 22531,759.880.31%ネガティブ


Share this page